aflo™ is a digital health company using smart technology to transform how people manage respiratory conditions.
Its smart inhaler platform teaches users how to inhale medication correctly and combines inhalation data with air quality and viral trends-empowering people with asthma and COPD to better manage their condition.
Originating as a spin-out supported by Ulster University and now part of the QUBIS portfolio, aflo™ brings together user-centred design, clinical evidence, and patented technology to support effective self-management and remote monitoring.
Proven impact:
- Addresses the 90% of patients who use their inhalers incorrectly.
- Demonstrated cost savings of €3,200+ per patient in the first year.
- Shown in trials to improve inhaler technique and symptom control.